ETAFENONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H27NO2
Molecular Weight	325.4446
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)CCOC1=CC=CC=C1C(=O)CCC2=CC=CC=C2

InChI

InChIKey=OEGDFSLNGABBKJ-UHFFFAOYSA-N

InChI=1S/C21H27NO2/c1-3-22(4-2)16-17-24-21-13-9-8-12-19(21)20(23)15-14-18-10-6-5-7-11-18/h5-13H,3-4,14-17H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C21H27NO2
Molecular Weight	325.4446
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23 | https://www.ncbi.nlm.nih.gov/pubmed/238542
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/6482088 | https://www.ncbi.nlm.nih.gov/pubmed/582134 | https://www.ncbi.nlm.nih.gov/pubmed/469443 | https://www.ncbi.nlm.nih.gov/pubmed/94412 | http://www.drugfuture.com/chemdata/etafenone.html | https://www.ncbi.nlm.nih.gov/pubmed/582134 | https://www.ncbi.nlm.nih.gov/pubmed/94412 | https://www.ncbi.nlm.nih.gov/pubmed/1037264 | https://www.ncbi.nlm.nih.gov/pubmed/1786372

Etafenone is an antiarrhythmic and coronary vasodilator drug. Etafenone exerts negative inotropic action on myocardium. It is able to block calcium channels. As a coronary vasodilator which produces a decrease in the heart rate and myocardial oxygen consumption, etafenone has been used in the therapy of ischemic heart disease.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D1 receptor 101 Target ID: CHEMBL3071 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10888308	Binding Agent 1064	2.43 µM [Ki]
Dopamine D2 receptor 297 Target ID: CHEMBL3427 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10888308	Binding Agent 1064	3.92 µM [Ki]
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2097162 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10888308	Binding Agent 1064	0.184 µM [Ki]
vascular smooth muscle contraction 5 Target ID: GO:0014829 Sources: http://www.kegg.jp/entry/D01440 \| https://www.ncbi.nlm.nih.gov/pubmed/23 \| https://www.ncbi.nlm.nih.gov/pubmed/238542	Inhibitor 8297
Voltage-gated calcium channel 37 Target ID: CHEMBL2363032 Sources: http://www.drugfuture.com/chemdata/etafenone.html \| https://www.ncbi.nlm.nih.gov/pubmed/582134 \| https://www.ncbi.nlm.nih.gov/pubmed/94412 \| https://www.ncbi.nlm.nih.gov/pubmed/1037264 \| https://www.ncbi.nlm.nih.gov/pubmed/1786372	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
Angina pectoris 106 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6482088	Primary		Approved 8429	DIALICOR Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Parenteral

In Vitro Use Guide

After etafenone 1 uM, there was a significant prolongation of the time to the detectable or the maximum increase in NADH fluorescence in isolated perfused guinea pig heart

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:38:48 GMT 2023` Edited by `admin` on `Fri Dec 15 16:38:48 GMT 2023`
Record UNII	0I14K589E7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ETAFENONE

Official Name

English

ETAFENONE [MI]

Common Name

English

etafenone [INN]

Common Name

English

Etafenone [WHO-DD]

Common Name

English

2'-(2-(DIETHYLAMINO)ETHOXY)-3-PHENYLPROPIOPHENONE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C48149